OlympiA was a double-blinded, phase III trial conducted to evaluate the safety and efficacy of adjuvant olaparib therapy versus placebo in high-risk, germline BRCA-mutated, HER2-negative early BC who received local treatment and neoadjuvant or adjuvant chemotherapy (at least 6 cycles anthracyclines or/and taxanes. This evidence concerns the gene ERBB2 and breast cancer.